Canada Markets closed

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.0500+0.0400 (+1.33%)
At close: 04:00PM EDT
3.1200 +0.07 (+2.30%)
After hours: 06:05PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • m
    manfredini
    AFMD looks like it is about to drop. Be careful guys. I have been reading (http://Achieverspot.tech) and their stocks have been doing way better.
  • B
    Brian
    Summary of Q2 report: the shares outstanding increased to 147,000,000 from 120,000,000 last year. R & D expenses decreased and the loss increased. There might be some news on P2 data later this year. At the rate that AFMD is progressing, target 2029 as the year that we'll find out if they really have something and divide it by an estimated 400,000,000 shares outstanding then.
  • J
    JAMES
    So once again it looks like the news today was not good or well liked ? Does anyone have any thoughts on what today means AFM28 ?? Thanks
  • S
    Stuart
    Somebody knows something
  • k
    karl shu
    AFM13 due to report this yr.
    Might be the FIRST NK cell related therapy to be approved.
  • C
    Carlos
    So, when are analysts posting new targets??
  • J
    Jos
    Tomorrow second quarter figures and conference call.
  • C
    Carlos
    6 by October
  • g
    gene_genome
    SVB Securities Adjusts Affimed Price Target to $9 From $10, Maintains Outperform Rating...
  • I
    IdGM4
    just proving monotherapy means buyout at $17.50 - $20.00
    afm24
    afm13
    afm28
  • J
    Jos
    I have seen the Affimed presentation at Jefferies this week. I personally like the approach they take. It may be early but it all looks promising and especially in 2023.
  • J
    Jos
    So far it seems that the majority of investors in this company are Europeans. In general it means that the share price is relatively low compared to US located companies irrespective of progress that would be valued otherwise if it was a US company in stead of a German company. This company however is well financed for its activities and its low valuation does make it an easy takeover target, though it is well financed and can continue its development if it is left alone by the big pharmaceutical.
  • B
    Brian
    Founded 22 years ago, they're only in Phase 2 trials.
    I'll check back in 2029 to see how they're doing.
    Will the shares count triple by then?
  • M
    Michael
    I see that Adi has a salary of $455k... but: award of options worth $2M and some misc to make his last year's income $2,785,265.00 while the share price dropped 50%... CFO Smith made 1.6M .. Seems they like the $$. Let's hope they produce.
    Some data to come soon and more by Dec 2022.
  • P
    Penny
    In comparison to other biotechs, many of which are selling below cash, some below half of cash value, a fair valuation for AFMD would be $200,000,000 or $1.35 per share.
  • J
    Jos
    Anyone to react on the press release re 24?
  • J
    Jos
    This week data will be presented at the annual cell engaged summit in Boston by mr Koch of Affimed.
  • S
    Sir John T
    I believe AFMD will become one of the best performing stocks of 2021... what we're seeing now only foretells good things on the horizon.
    Read the news releases, review the presentation, check out the management, board and pipeline. Look at their partnerships. Capitalization still very, very tiny relative to the above. Great institutional support...and more will be coming aboard in the next few weeks/months.

    I'm a long-term oriented long and holding for well beyond 2021. Just posting this to share my beliefs. As always, check things out for yourselves.

    Be well and stay safe.
  • a
    al
    August 7, 2019

    Heidelberg, Germany, August 7, 2019 - Affimed N.V. (AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today reported financial and operating results for the second quarter ended June 30, 2019.

    “After reaching agreement with the U.S. Food and Drug Administration on the study protocol design, we are now in the process of preparing to initiate the AFM13 registration-directed Phase 2 study,” said Dr. Adi Hoess, Affimed’s CEO. “The recent positive final and interim results from two clinical studies of AFM13 add to the growing body of evidence supporting AFM13’s activity in CD30-positive lymphoma patients, and give us increased confidence in the potential of AFM13 to demonstrate clinical benefit in CD30-positive peripheral T cell lymphoma. To execute the Phase 2 study and to further advance our internal and partnered CD16A-targeting innate cell engager pipeline, we have significantly strengthened our organization through the addition of multiple key hires in the U.S. and Germany of individuals who have substantial drug development experience.”
  • S
    Submarine
    Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas